A watchdog group said on Thursday the FDA was “lax” and “permissive” in its approval of a blood-thinner designed to prevent clots and strokes in patients with a heart condition that affects millions of Americans.
It has been a mixed week for the pharmaceutical sector in terms of drug development, with success for Novartis and disappointing news for Boehringer and Vitae Pharma. Digital Journal reports on the latest news.
The Frankfurter Allgemeine Zeitung news reported on Saturday that Germany's Bayer AG pharmaceutical company will be facing its first lawsuits in the U.S. this year over its anti-clotting drug, Xarelto, one of its top-five money makers.
